• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Index atherectomy peripheral vascular interventions performed for claudication are associated with more reinterventions than nonatherectomy interventions.索引动脉切除术外周血管介入治疗间歇性跛行与非动脉切除术介入治疗相比,需要更多的再次介入治疗。
J Vasc Surg. 2022 Aug;76(2):489-498.e4. doi: 10.1016/j.jvs.2022.02.034. Epub 2022 Mar 8.
2
Early peripheral vascular interventions for claudication are associated with higher rates of late interventions and progression to chronic limb threatening ischemia.早期外周血管介入治疗跛行与晚期介入治疗和进展为慢性肢体威胁性缺血的发生率较高相关。
J Vasc Surg. 2023 Mar;77(3):836-847.e3. doi: 10.1016/j.jvs.2022.10.025. Epub 2022 Oct 28.
3
Reprint of: Early peripheral vascular interventions for claudication are associated with higher rates of late interventions and progression to chronic limb threatening ischemia.早期外周血管介入治疗跛行与晚期介入治疗和进展为慢性肢体威胁性缺血的发生率较高相关。
J Vasc Surg. 2023 Jun;77(6):1720-1731.e3. doi: 10.1016/j.jvs.2023.04.023.
4
Use of Atherectomy During Index Peripheral Vascular Interventions.在指数外周血管介入治疗中使用旋切术。
JACC Cardiovasc Interv. 2021 Mar 22;14(6):678-688. doi: 10.1016/j.jcin.2021.01.004.
5
Practice patterns of peripheral vascular interventions for peripheral artery disease in the office-based laboratory setting versus outpatient hospital.在诊室内的基础实验室环境与门诊医院中,外周血管疾病的外周血管介入治疗的实践模式。
J Vasc Surg. 2024 Nov;80(5):1525-1536.e7. doi: 10.1016/j.jvs.2024.06.006. Epub 2024 Jun 20.
6
Practice patterns surrounding the use of tibial interventions for claudication in the Medicare population.在 Medicare 人群中,使用胫骨介入治疗跛行的实践模式。
J Vasc Surg. 2023 Feb;77(2):454-462.e1. doi: 10.1016/j.jvs.2022.08.033. Epub 2022 Sep 1.
7
Comparison of endovascular therapies for chronic limb-threatening ischemia and claudication.慢性肢体缺血性疾病和跛行的血管内治疗比较。
J Vasc Surg. 2024 Apr;79(4):875-886.e8. doi: 10.1016/j.jvs.2023.12.001. Epub 2023 Dec 7.
8
Overuse of early peripheral vascular interventions for claudication.过度使用早期外周血管介入治疗跛行。
J Vasc Surg. 2020 Jan;71(1):121-130.e1. doi: 10.1016/j.jvs.2019.05.005. Epub 2019 Jun 14.
9
Long-term outcomes of peripheral atherectomy for femoropopliteal endovascular interventions.股腘动脉腔内介入治疗中经皮血管腔内斑块旋切术的长期疗效。
EuroIntervention. 2023 Apr 3;18(16):e1378-e1387. doi: 10.4244/EIJ-D-22-00609.
10
Co-Morbidity Differences Associated With Long-Term Amputation and Repeat Revascularization Rates After Femoropopliteal Artery Intervention for Intermittent Claudication by Sex, Race, and Ethnicity.性别、种族和民族对间歇性跛行股腘动脉介入治疗后长期截肢和再次血运重建率相关共病的影响。
Am J Cardiol. 2024 Sep 1;226:40-49. doi: 10.1016/j.amjcard.2024.05.021. Epub 2024 Jun 2.

引用本文的文献

1
Validation of Codes to Distinguish Between Claudication and Chronic Limb-Threatening Ischemia in Patients Undergoing Peripheral Vascular Intervention Using Medicare-Matched Registry Data.利用医疗保险匹配登记数据验证区分接受外周血管介入治疗患者间歇性跛行和慢性肢体威胁性缺血的编码
Circ Cardiovasc Qual Outcomes. 2025 Jul;18(7):e011467. doi: 10.1161/CIRCOUTCOMES.124.011467. Epub 2025 May 29.
2
Use of Intravascular Ultrasound during Peripheral Vascular Interventions for Claudication Is Not Associated with Improved Outcomes.在间歇性跛行的外周血管介入治疗中使用血管内超声与改善预后无关。
Ann Vasc Surg. 2025 Oct;119:14-28. doi: 10.1016/j.avsg.2025.04.116. Epub 2025 Apr 29.
3
Association between Regional Market Competition and Early Femoropopliteal Interventions for Claudication.区域市场竞争与早期股腘动脉间歇性跛行干预之间的关联
Ann Vasc Surg. 2025 Jan;110(Pt B):424-433. doi: 10.1016/j.avsg.2024.09.047. Epub 2024 Oct 16.
4
What the National Coverage Determination for Carotid Artery Stenting Means for the Treatment of Patients with Carotid Artery Disease.《颈动脉支架置入术的国家医保覆盖范围判定对颈动脉疾病患者治疗的意义》
Ann Vasc Surg. 2025 Apr;113:337-345. doi: 10.1016/j.avsg.2024.09.037. Epub 2024 Oct 5.
5
Effectiveness of Atherectomy and Drug-Coated Balloon Angioplasty in Femoropopliteal Disease: A Comprehensive Outcome Study.斑块旋切术和药物涂层球囊血管成形术治疗股腘动脉疾病的疗效:一项综合结局研究
Vasc Specialist Int. 2024 Sep 30;40:34. doi: 10.5758/vsi.240071.
6
The Midterm Outcomes of Endovascular Therapy for Femoropopliteal Lesions via Drug-Coated Balloon, Directional Atherectomy and Bare Metal Stent Angioplasty.经药物涂层球囊、定向斑块旋切术和裸金属支架血管成形术治疗股腘动脉病变的血管内治疗中期结果
Rev Cardiovasc Med. 2024 Sep 18;25(9):331. doi: 10.31083/j.rcm2509331. eCollection 2024 Sep.
7
Trends and Factors Associated With Peripheral Vascular Interventions for the Treatment of Claudication From 2011 to 2022: A National Medicare Cohort Study.2011 年至 2022 年治疗间歇性跛行的外周血管介入治疗的趋势和相关因素:一项全国性医疗保险队列研究。
J Am Heart Assoc. 2024 Jul 16;13(14):e033463. doi: 10.1161/JAHA.123.033463. Epub 2024 Jul 3.
8
Editor's Choice - Infrapopliteal Peripheral Vascular Interventions for Claudication are Performed Frequently in the USA and Are Associated with Poor Long Term Outcomes.编辑推荐——美国频繁进行用于治疗间歇性跛行的腘下周围血管介入治疗,且其长期预后不佳。
Eur J Vasc Endovasc Surg. 2025 Jan;69(1):89-101. doi: 10.1016/j.ejvs.2024.06.017. Epub 2024 Jun 19.
9
Infrapopliteal Endovascular Interventions for Claudication Are Associated with Poor Long-Term Outcomes in Medicare-Matched Registry Patients.在医疗保险匹配登记患者中,腘下血管腔内介入治疗间歇性跛行的长期预后较差。
Ann Surg. 2024 Jun 6. doi: 10.1097/SLA.0000000000006368.
10
Appropriateness of Care Measures: A Novel Approach to Quality.适宜性护理措施:一种新颖的质量方法。
Ann Vasc Surg. 2024 Oct;107:186-194. doi: 10.1016/j.avsg.2024.01.029. Epub 2024 Apr 4.

本文引用的文献

1
Effects of Peripheral Arterial Disease Interventions on Survival: A Propensity-Score Matched Analysis Using VQI Data.外周动脉疾病干预对生存的影响:使用VQI数据的倾向评分匹配分析
Ann Vasc Surg. 2022 Feb;79:162-173. doi: 10.1016/j.avsg.2021.08.004. Epub 2021 Oct 10.
2
Trends in Utilization and Outcomes of Orbital, Laser, and Excisional Atherectomy for Lower Extremity Revascularization.下肢血运重建中环锯、激光和旋切斑块切除术的应用和结局趋势。
J Endovasc Ther. 2022 Jun;29(3):389-401. doi: 10.1177/15266028211050329. Epub 2021 Oct 13.
3
Critical appraisal of the contemporary use of atherectomy to treat femoropopliteal atherosclerotic disease.对当代采用旋切术治疗股腘动脉粥样硬化性疾病的方法进行评价。
J Vasc Surg. 2022 Feb;75(2):697-708.e9. doi: 10.1016/j.jvs.2021.07.106. Epub 2021 Jul 22.
4
Atherectomy Combined with Balloon Angioplasty versus Balloon Angioplasty Alone for de Novo Femoropopliteal Arterial Diseases: A Systematic Review and Meta-analysis of Randomised Controlled Trials.血管内斑块旋切术联合球囊血管成形术与单纯球囊血管成形术治疗新发股腘动脉疾病的随机对照试验的系统评价和 Meta 分析。
Eur J Vasc Endovasc Surg. 2021 Jul;62(1):65-73. doi: 10.1016/j.ejvs.2021.02.012. Epub 2021 Jun 8.
5
Atherectomy in Peripheral Vascular Interventions: Time to Follow the Guidelines?外周血管介入治疗中的旋切术:是时候遵循指南了吗?
JACC Cardiovasc Interv. 2021 Mar 22;14(6):689-691. doi: 10.1016/j.jcin.2021.01.041.
6
Use of Atherectomy During Index Peripheral Vascular Interventions.在指数外周血管介入治疗中使用旋切术。
JACC Cardiovasc Interv. 2021 Mar 22;14(6):678-688. doi: 10.1016/j.jcin.2021.01.004.
7
Intermittent claudication treatment patterns in the commercially insured non-Medicare population.商业保险非老年医保人群间歇性跛行的治疗模式。
J Vasc Surg. 2021 Aug;74(2):499-504. doi: 10.1016/j.jvs.2020.10.090. Epub 2021 Feb 4.
8
Endovascular interventions for claudication do not meet minimum standards for the Society for Vascular Surgery efficacy guidelines.血管内介入治疗跛行不符合血管外科学会疗效指南的最低标准。
J Vasc Surg. 2021 May;73(5):1693-1700.e3. doi: 10.1016/j.jvs.2020.10.067. Epub 2020 Nov 27.
9
Atherectomy for peripheral arterial disease.外周动脉疾病的旋切术
Cochrane Database Syst Rev. 2020 Sep 29;9(9):CD006680. doi: 10.1002/14651858.CD006680.pub3.
10
Preliminary Results of the Outpatient Endovascular and Interventional Society National Registry.门诊血管外科学和介入学会国家注册研究初步结果。
J Endovasc Ther. 2020 Dec;27(6):956-963. doi: 10.1177/1526602820949970. Epub 2020 Aug 19.

索引动脉切除术外周血管介入治疗间歇性跛行与非动脉切除术介入治疗相比,需要更多的再次介入治疗。

Index atherectomy peripheral vascular interventions performed for claudication are associated with more reinterventions than nonatherectomy interventions.

机构信息

Department of Plastics and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.

出版信息

J Vasc Surg. 2022 Aug;76(2):489-498.e4. doi: 10.1016/j.jvs.2022.02.034. Epub 2022 Mar 8.

DOI:10.1016/j.jvs.2022.02.034
PMID:35276258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9329163/
Abstract

OBJECTIVE

Despite limited evidence supporting atherectomy alone over stenting/angioplasty as the index peripheral vascular intervention (PVI), the use of atherectomy has rapidly increased in recent years. We previously identified a wide distribution of atherectomy practice patterns among US physicians. The aim of this study was to investigate the association of index atherectomy with reintervention.

METHODS

We used 100% Medicare fee-for-service claims to identify all beneficiaries who underwent elective first-time femoropopliteal PVI for claudication between January 1, 2019, and December 31, 2019. Subsequent PVI reinterventions were examined through June 30, 2021. Kaplan-Meier curves were used to compare rates of PVI reinterventions for patients who received index atherectomy versus nonatherectomy procedures. Reintervention rates were also described for physicians by their overall atherectomy use (by quartile). A hierarchical Cox proportional hazard model was used to evaluate patient and physician-level characteristics associated with reinterventions.

RESULTS

A total of 15,246 patients underwent an index PVI for claudication in 2019, of which 59.7% were atherectomy. After a median of 603 days (interquartile range, 77-784 days) of follow-up, 41.2% of patients underwent a PVI reintervention, including 48.9% of patients who underwent index atherectomy versus 29.8% of patients who underwent index nonatherectomy (P < .001). Patients treated by high physician users of atherectomy (quartile 4) received more reinterventions than patients treated by standard physician users (quartiles 1-3) (56.8% vs 39.6%; P < .001). After adjustment, patient factors association with PVI reintervention included receipt of index atherectomy (adjusted hazard ratio [aHR], 1.33; 95% confidence interval [CI], 1.21-1.46), Black race (vs White; aHR; 1.18; 95% CI, 1.03-1.34), diabetes (aHR, 1.13; 95% CI, 1.07-1.21), and urban residence (aHR, 1.11; 95% CI, 1.01-1.22). Physician factors associated with reintervention included male sex (aHR, 1.52; 95% CI, 1.12-2.04), high-volume PVI practices (aHR, 1.23; 95% CI, 1.10-1.37), and physicians with a high use of index atherectomy (aHR, 1.49; 95% CI, 1.27-1.74). Vascular surgeons had a lower risk of PVI reintervention than cardiologists (vs vascular; aHR, 1.22; 95% CI, 1.09-1.38), radiologists (aHR, 1.55; 95% CI, 1.31-1.83), and other specialties (aHR, 1.59; 95% CI, 1.20-2.11). The location of services delivered was not associated with reintervention (P > .05).

CONCLUSIONS

The use of atherectomy as an index PVI for claudication is associated with higher PVI reintervention rates compared with nonatherectomy procedures. Similarly, high physician users of atherectomy perform more PVI reinterventions than their peers. The appropriateness of using atherectomy for initial treatment of claudication needs critical reevaluation.

摘要

目的

尽管有有限的证据支持单纯血管成形术/支架置入术优于血管内膜切除术作为外周血管介入治疗(PVI)的索引,但近年来血管内膜切除术的使用迅速增加。我们之前发现美国医生之间存在广泛的血管内膜切除术的治疗模式。本研究旨在探讨索引血管内膜切除术与再干预的关系。

方法

我们使用 100%的 Medicare 按服务收费数据来确定 2019 年 1 月 1 日至 12 月 31 日期间因跛行而首次接受股腘 PVI 的所有受益人的情况。通过 2021 年 6 月 30 日来检查后续的 PVI 再干预。使用 Kaplan-Meier 曲线比较接受索引血管内膜切除术与非血管内膜切除术患者的 PVI 再干预率。还按医生的整体血管内膜切除术使用率(四分位数)描述了医生的再干预情况。使用分层 Cox 比例风险模型评估与再干预相关的患者和医生特征。

结果

2019 年共有 15246 名患者因跛行进行了指数 PVI,其中 59.7%为血管内膜切除术。在中位随访 603 天(四分位距 77-784 天)后,41.2%的患者进行了 PVI 再干预,其中 48.9%的患者接受了索引血管内膜切除术,而 29.8%的患者接受了索引非血管内膜切除术(P <.001)。高血管内膜切除术使用率的医生治疗的患者(四分位数 4)比标准血管内膜切除术使用率的医生治疗的患者(四分位数 1-3)接受的再干预更多(56.8%比 39.6%;P <.001)。在调整后,与 PVI 再干预相关的患者因素包括接受索引血管内膜切除术(调整后的危险比 [aHR],1.33;95%置信区间 [CI],1.21-1.46)、黑种人(与白种人相比;aHR,1.18;95%CI,1.03-1.34)、糖尿病(aHR,1.13;95%CI,1.07-1.21)和城市居住(aHR,1.11;95%CI,1.01-1.22)。与再干预相关的医生因素包括男性(aHR,1.52;95%CI,1.12-2.04)、高 PVI 手术量(aHR,1.23;95%CI,1.10-1.37)和高索引血管内膜切除术使用率的医生(aHR,1.49;95%CI,1.27-1.74)。血管外科医生比心脏病专家(与血管外科医生相比;aHR,1.22;95%CI,1.09-1.38)、放射科医生(aHR,1.55;95%CI,1.31-1.83)和其他专业医生(aHR,1.59;95%CI,1.20-2.11)的 PVI 再干预风险更低。服务提供地点与再干预无关(P >.05)。

结论

与非血管内膜切除术相比,血管内膜切除术作为索引 PVI 治疗跛行与更高的 PVI 再干预率相关。同样,高血管内膜切除术使用率的医生比他们的同行进行更多的 PVI 再干预。使用血管内膜切除术作为初始治疗跛行的适当性需要进行批判性重新评估。